Risk of Cognitive Decline in Older Patients With Newly Diagnosed Stage 0-III Breast Cancer

Inclusion Criteria

• CANCER PATIENTS:
• Diagnosis of a new primary histological confirmed breast cancer
• American Joint Committee on Cancer (AJCC) stages 0-3 or planning on undergoing neoadjuvant therapy
• CANCER PATIENTS AND CONTROLS:
• In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent
• If currently taking psychoactive medications (including, but not limited to anticonvulsants, antidepressants, and anxiolytics), dose must have been stable at least two months prior to enrollment

Exclusion Criteria

• Participant report of a history of formal diagnosis of neurodegenerative disorders that affect cognition (i.e. Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, dementia, seizure disorders, etc.)
• Participant report of surgery on the brain for any reason (cancerous or non-cancerous tumors, subdural hematomas, arteriovenous [AV] malformations, increased intracranial pressure, etc.)
• Participant report of a history of stroke (with the exception of transient ischemic attack [TIA] if >= 1 year ago)
• Participant report of human immunodeficiency (HIV)/acquired immunodeficiency syndrome (AIDS)
• Participant report of moderate to severe head trauma (loss of consciousness > 60 min or with evidence of structural brain changes on imaging)
• History of major psychiatric disorder (Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV Axis 1) (i.e. major depressive disorder (untreated or poorly treated), bipolar disorders, schizophrenia, or substance abuse disorders (self-reported and/or stated in medical record)
• Participant report of a history of prior breast or other cancer with the exception of non-melanoma skin cancer * An exception for cases only: women who completed treatment for a previous cancer at least 5 years ago and have not undergone any chemotherapy or hormonal therapy; this previous cancer cannot be breast cancer
• Participant report of previous or current chemotherapy or hormonal therapy use
• Participant use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn’s disease, or cyclophosphamide (Cytoxan, Neosar) for Lupus
• Visual or hearing impairment that would preclude ability to complete interviews or neuropsychological testing, such as significant macular degeneration or being unable to correct hearing with hearing aides
• Non-English speaking
• To participate in the optional neuroimaging portion of the study: * Participant cannot be claustrophobic * Participant cannot have a pacemaker, aneurysm clip or other implants that are not magnetic resonance imaging (MRI) safe * Participant cannot have any type of implanted electrical device